CDXS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Codexis Inc (CDXS) is not a strong buy at the moment for a beginner investor with a long-term focus. While there are some positive catalysts, such as the recent partnership for siRNA production, the company's financial performance is weak, and insider selling is a negative indicator. Additionally, technical indicators and trading signals do not suggest a compelling entry point.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI is neutral at 70.082, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its resistance level of 1.239, which may limit immediate upside potential.
Codexis has entered into a significant partnership to produce siRNA for preclinical development, marking an entry into a high-volume market opportunity. The ECO Synthesis platform addresses growing manufacturing demands in RNA therapeutics.
Hedge funds are neutral, and no recent congress trading data is available.
In Q3 2025, revenue dropped by 32.98% YoY to $8.6M, net income fell by 4.97% YoY to -$19.6M, and EPS declined by 24.14% YoY to -0.22. However, gross margin improved by 7.50% YoY to 71.34%.
No recent analyst rating or price target changes were provided in the data.
